News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–22
Matches
22
Sources here
13
Companies here
1
Search results Stored financial headlines

Active search

22 matching headlines

Ticker or company: AGMBMain company stories
Clear
Latest

Stock Titan Market update

Agomab Therapeutics (AGMB) seeks two new directors, calls Sept. 11, 2026 shareholder meetings

Agomab Therapeutics (AGMB) has announced a special and extraordinary general shareholders' meeting for September 11, 2026, in Antwerp, Belgium. The company plans to propose the appointment of Marino Garcia and Dr. Naimish Patel as non-executive directors for four-year terms, subject to shareholder approval. Additionally, the meeting will address the consolidation and split of pre-IPO subscription rights to simplify …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Just inNext headlines
www.marketscreener.com Market update Main company 🇺🇸 United States

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

Agomab Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel to its Board of Directors, pending shareholder approval at a Special General Meeting on September 11, 2026. Marino Garcia brings extensive experience in biotechnology leadership and financing, currently serving as …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingView Analyst action Main company 🇺🇸 United States

AgomAb Therapeutics NV Stock 12‑Month Price Target Cut to $33.16, Implies 146% Upside

AgomAb Therapeutics NV's average 12-month price target has been lowered slightly from $34.2 to $33.16 by six analysts, with forecasts ranging from $27.96 to $36.27 per share. Despite the cut, this updated target still suggests a significant upside of approximately 146% from its recent …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

The Manila Times Earnings Main company 🇺🇸 United States

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Agomab Therapeutics NV reported its financial results for the first half of 2026, confirming its outlook for the second half of the year. The company successfully completed its Nasdaq IPO, raising $208 million, which is expected to fund operations into the first half of …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Agomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029

Agomab Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of €30.97 million for the first half of 2026 but secured its financial future by raising $208 million in gross proceeds from a Nasdaq IPO. This capital infusion, bringing their total cash and investments …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Agomab reports €252M cash and expects runway into H1 2029

Agomab (Nasdaq: AGMB) reported a net loss of €31.0 million for the first half of 2026, with €252.0 million in cash and short-term investments as of June 30, 2026. This cash position, bolstered by a $208 million IPO, is expected to fund operations into …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Sahm Balance sheet Main company 🇺🇸 United States

We Think AgomAb Therapeutics (NASDAQ:AGMB) Can Afford To Drive Business Growth

AgomAb Therapeutics (NASDAQ:AGMB), despite being unprofitable, is considered to have a manageable cash burn. With €117m in cash reserves and a burn rate of €52m per year, the company has a cash runway of about 2.3 years. While its cash burn increased by 8.9% …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
www.marketscreener.com Market update Main company 🇺🇸 United States

Certain Warrants of AgomAb Therapeutics NV are subject to a Lock-Up Agreement Ending on 5-AUG-2026.

Certain warrants of AgomAb Therapeutics NV are under a lock-up agreement set to expire on August 5, 2026. These warrants will be locked up for a period of 181 days, beginning February 5, 2026. The agreement applies to directors, executive officers, and substantially all …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

AgomAb Therapeutics (Nasdaq:AGMB) - Stock Analysis

This article provides a stock analysis of AgomAb Therapeutics (AGMB), a clinical-stage biopharmaceutical company. It highlights the company's financial

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Enterprise value to revenue forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article focuses on the enterprise value to revenue forward of AgomAb Therapeutics NV (NASDAQ:AGMB). It provides a high-level overview of the company's financials as presented on TradingView. The content itself is very minimal, serving more as a title for a financial data point …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

Price to sales forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article provides a brief snapshot of AgomAb Therapeutics NV's (NASDAQ: AGMB) "Price to sales forward" metric. It appears to be a financial data point from TradingView, indicating a period value, change, and percentage change. The article focuses on presenting this specific financial data …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Price to earnings forward of AgomAb Therapeutics NV – NASDAQ:AGMB

This article provides the "Price to earnings forward" value for AgomAb Therapeutics NV (NASDAQ: AGMB). It shows that for the specified period, the value is listed as "No trades." The information is presented within a financial data context.

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

AgomAb Therapeutics NV Revenue Breakdown – NASDAQ:AGMB

This article displays the revenue breakdown for AgomAb Therapeutics NV, trading under the NASDAQ symbol AGMB. It provides a financial overview of the company, focusing on fundamentals, statements, statistics, dividends, earnings, and segment performance. The content includes links to various financial data and tools …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026
Investing.com India Analyst action Main company 🇺🇸 United States

B.Riley initiates Agomab Therapeutics stock with buy rating

B.Riley has initiated coverage on Agomab Therapeutics (NASDAQ:AGMB) with a "buy" rating and a price target of $34.00, suggesting a nearly 200% upside from its current trading price of $11.60. The firm highlights Agomab's focus on developing organ-restricted small-molecule inhibitors for fibrosis, particularly in …

AGMB main company
Sharemaestro market context Stored weekly price path 28 weeks -9.8% AGMB stored weekly price path from 6 Feb 2026 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context